



1647

Please type a plus sign (+) inside this box →

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1>TRANSMITTAL FORM</h1> <p><i>(to be used for all correspondence after initial filing)</i></p>	Application Number	09/898,751	
	Filing Date	July 2, 2001	
	First Named Inventor	Wei Wang	
	Group Art Unit	1647	
	Examiner Name	Bunner, Bridget	
Total Number of Pages in This Submission	14	Attorney Docket Number	DX0882XK

RECEIVED

MAR 06 2003

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	7 References w/Response Certificate of Mailing 1 pg. Return Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Sandy Zaradic, Reg. No. 45,997
Signature	
Date	February 28, 2003

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:		
Typed or printed name		
Signature	Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Attorney Docket No.: DX0882XK

Serial No.: 09/898,751

Filing Date: July 2, 2001

Inventor: Wei Wang

PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:


**Assistant Commissioner for Patents
Washington, D.C. 20231**

on February 28, 2003
Date

RECEIVED

MAR 06 2003

TECH CENTER 1600/2900


Signature

SANDY ZARADIC, Reg. No. 45,997
Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents enclosed:

- Transmittal Sheet - 1 page
- Response to Office Action - 12 pages
- References in support of Response - 7
- Certificate of Mailing- 1 page
- Return Postcard

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT CASE: DX0882XK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#13B/KW
031803

-----X	:	
In re Application of: Wei Wang <i>et al.</i>	:	Examiner: Bunner, Bridget E.
	:	
For: Chemokine and Receptor Uses;	:	Group Art Unit: 1647
Compositions; Methods	:	
	:	
Serial No.: 09/898,751	:	
	:	
Filing Date: July 2, 2001	:	
-----X	:	

RECEIVED

MAR 06 2003

February 28, 2003

Assistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

RESPONSE TO OFFICE ACTION

This is in response to the Office Action, Paper No. 12, (Confirmation No. 7429) mailed November 29, 2002, for which a response is due February 28, 2003.

PLEASE AMEND THE APPLICATION AS FOLLOWS:

IN THE SPECIFICATION

Prior to the first sentence of the specification, please include the following:

B1

This is a continuation-in-part of U.S. Application No. 09/471,549, filed December 23, 1999, now abandoned.

At the top of pages 1 and 102, please replace the present title with the following title:

METHOD OF IMPAIRING MOVEMENT OF A CLA⁺ MEMORY T-CELL WITHIN OR TO THE SKIN OF A MAMMAL BY ADMINISTERING A CTACK ANTAGONIST.

On page 9, lines 3-20, please replace the present pending text with the following:

B2

The described chemokines or receptors should be important for mediating various aspects of cellular, organ, tissue, or organismal physiology or development. In particular, the Vic chemokine is a classic pro-inflammatory chemokine, which mediates inflammatory processes. The CTACK is a cutaneously expressed chemokine. See, e.g., USSN 08/978,964 (now abandoned) and related cases.

In contrast to naive lymphocytes, memory/effector lymphocytes can access non-lymphoid effector sites and display restricted, often tissue-selective, migration behavior. The cutaneous lymphocyte-associated antigen (CLA) defines a well described subset of circulating memory T cells that selectively localize in cutaneous sites mediated in part by the interaction of CLA with its vascular ligand E-selectin. Picker, et al. (1991) *Nature* 349:796-799; and Rossiter, et al. (1994) *Eur. J. Immunol.* 24:205-210. E-selectin is broadly expressed in inflamed endothelium; thus, specific infiltration of skin by CLA⁺ cells must require additional cues. Herein is description of particular C-C chemokines, one originally designated GWCC but herein referred to as